New life for Toyama compound in brain damage recovery

A paper in Science suggests collapsin response mediator protein-2 (DPYSL2; CRMP-2)-binding small molecule edonerpic maleate (T-817MA), which missed the primary endpoints in a Phase II trial for Alzheimer’s disease, could speed recovery from brain damage.

Last year, Fujifilm Holdings Corp. (Tokyo:4901) said edonerpic maleate -- discovered by Fujifilm subsidiary Toyama Chemical Co. Ltd. -- did not significantly improve cognition or global clinical function vs. placebo in the Phase II trial. However, Fujifilm reported that edonerpic maleate did significantly delay cognitive decline in patients diagnosed with AD for less than 2.6 years (see BioCentury Extra, July 19, 2017)...